Clinical Trial

Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will 1) Evaluate the prevalence of elevated (conditional or abnormal) transcranial Doppler (TCD) velocities in a cross-sectional analysis of children with Sickle Cell Anemia (SCA) living in Tanzania; 2) Obtain longitudinal data on TCD velocities in this population; and 3) Measure the effects of hydroxyurea therapy on TCD velocities and associated primary stroke risk.
Protocol Amendment History 2 changes
critical Trial status changed: Enrolling by Invitation → Active, Not Recruiting 2026-08-15
notable Primary completion moved earlier: 2026-12-31 -> 2022-09-05 2026-08-15
Trial Details
NCT Number NCT03948867
Lead Sponsor Children's Hospital Medical Center, Cincinnati
Collaborators: Bugando Medical Centre, The American Society of Hematology
Conditions Sickle Cell Anemia in Children
Enrollment 202 participants
Start Date 2019-04-24
Primary Completion 2022-09-05 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14